1. ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL). (17th June 2021) Authors: Salles, G; Goswami, B; Bagnardi, V; Dey, D; Winderlich, M; Ambarkhane, S; Huang, D; Nowakowski, G. S Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL). (17th June 2021) Authors: Salles, G; Goswami, B; Bagnardi, V; Dey, D; Winderlich, M; Ambarkhane, S; Huang, D; Nowakowski, G. S Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. (9th February 2018) Authors: Jurczak, W; Zinzani, P L; Gaidano, G; Goy, A; Provencio, M; Nagy, Z; Robak, T; Maddocks, K; Buske, C; Ambarkhane, S; Winderlich, M; Dirnberger-Hertweck, M; Korolkiewicz, R; Blum, K A Journal: Annals of oncology Issue: Volume 29:Number 5(2018) Page Start: 1266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗